共 50 条
- [42] LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Schimanski, C. C.Galle, P. R.Lang, H.Schoen, M.Moehler, M. H.
- [43] Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialLANCET ONCOLOGY, 2017, 18 (03) : 393 - 403Coens, CorneelSuciu, StefanChiarion-Sileni, VannaGrob, Jean-JacquesDummer, ReinhardWolchok, Jedd D.Schmidt, HenrikHamid, OmidRobert, CarolineAscierto, Paolo A.Richards, Jon M.Lebbe, CelesteFerraresi, VirginiaSmylie, MichaelWeber, Jeffrey S.Maio, MicheleBottomley, AndrewKotapati, Srividyade Pril, VeerleTestori, AlessandroEggermont, Alexander M. M.
- [44] Efficacy and safety of inhaled Zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: A 28-day, multicenter, randomized, double-blind, placebo-controlled trialCLINICAL THERAPEUTICS, 2007, 29 (08) : 1579 - 1590LaForce, CraigMan, Choy Y.Henderson, Frederick W.McElhaney, Janet E.Hampel, Frank C., Jr.Bettis, RobertKudule, LailaHarris, JuliaYates, PhilipTisdale, MargaretWebster, Alison
- [45] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trialANNALS OF ONCOLOGY, 2020, 31 : S1175 - S1175Eggermont, A. M. M.Blank, C. U.Mandala', M.Long, G. V.Atkinson, V.Dalle, S.Haydon, A. M.Meshcheryakov, A.Khattak, A.Carlino, M.Sandhu, S.Sarda, S. PuigAscierto, P. A.van Akkooi, A. C. J.Krepler, C.Ibrahim, N.Marreaud, S. I.Kicinski, M.Suciu, S.Robert, C.
- [46] Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trialBMJ OPEN, 2021, 11 (12):Hogh, StinneHegaard, Hanne KristineRenault, Kristina MarthaCvetanovska, EleonoraKjaerbye-Thygesen, AnetteJuul, AndersBorgsted, CamillaBjertrup, Anne JuulMiskowiak, Kamilla WoznicaVaever, Mette SkovgaardStenbaek, Dea SiggaardDam, Vibeke HoyrupBinder, ElisabethOzenne, BriceMehta, DivyaFrokjaer, Vibe G.
- [47] BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+melanoma at high risk for recurrenceANNALS OF ONCOLOGY, 2017, 28Lewis, K.Maio, M.Demidov, L.Mandala, M.Ascierto, P. A.Herbert, C.Mackiewicz, A.Rutkowski, P.Guminski, A.Goodman, G.Simmons, B.Ye, C.Yan, Y.Schadendorf, D.
- [48] ORAL 5-AMINOSALYCILIC ACID (5-ASA) IN THE PREVENTION OF EARLY RELAPSE OF CROHNS-DISEASE - INTERIM ANALYSIS OF A MULTICENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIALGASTROENTEROLOGY, 1994, 106 (04) : A670 - A670DEFRANCHIS, RBRIGNOLA, CDELPIANO, MOMODEI, PPERA, ARANZI, TROCCA, RVECCHI, M
- [49] Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontaminationIntensive Care Medicine, 2002, 28 : 1708 - 1717Jorge GarbinoDaniel P. LewJacques-A. RomandStéphane HugonnetRaymond AuckenthalerDidier Pittet
- [50] A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaBLOOD, 2017, 130Brighton, TimothyHarrison, Simon J.Ghez, DavidWeiss, Brendan M.Kirsch, AndreasMagen, HilaGironella, MercedesOriol, AlbertStreetly, MatthewQin, XiangBandekar, RajeshHu, PeterQi, MingNemat, SepidehGoldschmidt, Hartmut